<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">684367</article-id><article-id pub-id-type="doi">10.26442/20795696.2026.2.203569</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modern approaches to fertility preservation in women with endometrial hyperplasia, atypical endometrial hyperplasia, and low-grade endometrial adenocarcinoma: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Современные подходы к сохранению фертильности у женщин с гиперплазией эндометрия, атипической гиперплазией эндометрия и аденокарциномой эндометрия низкой степени злокачественности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6927-3336</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhurman</surname><given-names>Varvara N.</given-names></name><name xml:lang="ru"><surname>Журман</surname><given-names>Варвара Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. акушерства и гинекологии; врач-онколог</p></bio><email>varvara2007@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5404-4215</contrib-id><name-alternatives><name xml:lang="en"><surname>Matyushkina</surname><given-names>Lyudmila S.</given-names></name><name xml:lang="ru"><surname>Матюшкина</surname><given-names>Людмила Семеновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Assoc. Prof.</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц., зав. каф. акушерства и гинекологии</p></bio><email>varvara2007@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7352-2063</contrib-id><name-alternatives><name xml:lang="en"><surname>Shatnykh</surname><given-names>Anastasia A.</given-names></name><name xml:lang="ru"><surname>Шатных</surname><given-names>Анастасия Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор каф. акушерства и гинекологии</p></bio><email>varvara2007@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pacific State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Тихоокеанский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Primorsky Regional Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Приморский краевой онкологический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-11" publication-format="electronic"><day>11</day><month>07</month><year>2026</year></pub-date><volume>28</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>149</fpage><lpage>155</lpage><history><date date-type="received" iso-8601-date="2025-06-14"><day>14</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-06-30"><day>30</day><month>06</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/684367">https://gynecology.orscience.ru/2079-5831/article/view/684367</self-uri><abstract xml:lang="en"><p>Preserving the reproductive potential of women with endometrial diseases is an urgent task of modern reproductive medicine due to the increase in their prevalence and the fact that many women postpone pregnancy to a later age, which is especially common in developed countries. The article reviews the literature published in recent years on modern approaches to preserving fertility in patients with endometrial hyperplasia and low-grade endometrial adenocarcinoma, including organ-preserving therapies and methods to realize reproductive potential after treatment, as well as assessment of the endometrium after treatment and the use of assisted reproductive technologies. Organ-preserving therapy for endometrial hyperplasia aims to optimize oncological and reproductive outcomes while minimizing side effects. Hormone therapy used in these disorders contributes to a decrease in the receptive properties of the endometrium and reduces the probability of pregnancy. Therefore, despite attempts to optimize treatment, after hormonal therapy, patients with endometrial hyperplasia without atypia, as well as with atypical endometrial hyperplasia and low-grade endometrial adenocarcinoma of reproductive age, face problems in achieving pregnancy. The lack of standardized approaches to assessing the recovery of implantation properties of the endometrium makes it difficult to develop pregnancy planning programs after treatment for such patients of fertile age.</p></abstract><trans-abstract xml:lang="ru"><p>Сохранение репродуктивного потенциала женщин с патологией эндометрия представляет собой актуальную задачу современной репродуктивной медицины. Вопрос сохранения фертильности при патологиях эндометрия становится все более значимым, поскольку, с одной стороны, растет число женщин с такими заболеваниями, а с другой – все больше женщин откладывают беременность на более поздний возраст, что особенно заметно в развитых странах. Статья включает обзор опубликованных за последние годы литературных данных о современных подходах к сохранению фертильности у пациенток с гиперпластическими заболеваниями эндометрия и аденокарциномой эндометрия низкой степени злокачественности, включая методы органосохраняющей терапии и способы реализации репродуктивного потенциала после перенесенного лечения, в том числе оценку состояния эндометрия после лечения и применение вспомогательных репродуктивных технологий. Органосохраняющая терапия при гиперпластических процессах эндометрия направлена на оптимизацию онкологических и репродуктивных исходов при одновременном сведении к минимуму побочных эффектов. Гормональная терапия, используемая при данных патологиях, способствует снижению рецептивных свойств эндометрия и уменьшает вероятность наступления беременности. Следовательно, несмотря на попытки оптимизации лечения, после проведенной гормональной терапии пациентки с гиперплазией эндометрия без атипии, а также с атипической гиперплазией эндометрия и аденокарциномой эндометрия низкой степени злокачественности, находящиеся в репродуктивном возрасте, сталкиваются с проблемами наступления беременности. Отсутствие стандартизированных подходов к оценке восстановления имплантационных свойств эндометрия при указанных патологиях затрудняет разработку программ планирования беременности после перенесенной терапии для пациенток фертильного возраста.</p></trans-abstract><kwd-group xml:lang="en"><kwd>endometrial hyperplasia</kwd><kwd>endometrial adenocarcinoma</kwd><kwd>endometrial cancer</kwd><kwd>pregnancy</kwd><kwd>fertility</kwd><kwd>hormone therapy</kwd><kwd>gestagens</kwd><kwd>organ-preserving therapy</kwd><kwd>assisted reproductive technologies</kwd><kwd>reproductive medicine</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гиперплазия эндометрия</kwd><kwd>аденокарцинома эндометрия</kwd><kwd>рак эндометрия</kwd><kwd>беременность</kwd><kwd>фертильность</kwd><kwd>гормональная терапия</kwd><kwd>гестагены</kwd><kwd>органосохраняющая терапия</kwd><kwd>вспомогательные репродуктивные технологии</kwd><kwd>репродуктивная медицина</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gao S, Wang J, Li Z, et al. Global Trends in Incidence and Mortality Rates of Endometrial Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of Disease. Int J Womens Health. 2025;17:651-62. DOI:10.2147/IJWH.S499435</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Гусейнова Р.Г., Ордиянц И.М., Ямурзина А.А., и др. Злокачественная трансформация гиперплазированного эндометрия: эпидемиология и прогнозирование. Акушерство и гинекология: новости, мнения, обучение. 2020;8(3):100-5 [Huseynova RG, Ordiyants IM, Yamurzina AA, et al. Malignant transformation of endometrial hyperplasia: epidemiology and prognosis. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2020;8(3):100-5 (in Russian)]. DOI:10.24411/2303-9698-2020-13916</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Constantine GD, Kessler G, Graham S, Goldstein SR. Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors. J Womens Health (Larchmt). 2019;28(2):237-43. DOI:10.1089/jwh.2018.6956</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jang S, Hwang SO. Risk factors for atypical hyperplasia or endometrial cancer in premenopausal women aged ≤ 45 years with abnormal uterine bleeding. Eur J Obstet Gynecol Reprod Biol. 2024;302:288-93. DOI:10.1016/j.ejogrb.2024.09.030</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>De Rocco S, Buca D, Oronzii L, et al. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;273:90-7. DOI:10.1016/j.ejogrb.2022.04.019</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. DOI:10.1136/ijgc-2020-002230</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412-28. DOI:10.1016/S0140-6736(22)00323-3</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Злокачественные новообразования в России в 2024 г. (заболеваемость). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой, Н.Ю. Золотарева. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. 178 с. [Zlokachestvennye novoobrazovaniia v Rossii v 2024 g. (zabolevaemost'). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi, NIu Zolotareva. Moscow: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii, 2025. 178 p. (in Russian)].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Статистика рака эндометрия. WHO – Global Cancer Observatory: World Health Organization. 2025. Режим доступа: https://www.wcrf.org/preventing-cancer/cancer-statistics/endometrial-cancer-statistics/#latest-endometrial-cancer-data. Ссылка активна на 15.05.2025 [Statistika raka endometriia. WHO – Global Cancer Observatory: World Health Organization. 2025. Available at: https://www.wcrf.org/preventing-cancer/cancer-statistics/endometrial-cancer-statistics/#latest-endometrial-cancer-data. Accessed: 15.05.2025 (in Russian)].</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. DOI:10.3322/caac.21708</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Рак тела матки и саркомы матки. Клинические рекомендации Минздрава России. 2025. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/460_4. Ссылка активна на 15.05.2025 [Rak tela matki i sarkomy matki. Klinicheskie rekomendatsii Minzdrava Rossii. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/460_4. Accessed: 15.05.2025 (in Russian)].</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Uccella S, Zorzato PC, Dababou S, et al. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas). 2022;58(9). DOI:10.3390/medicina58091256</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Female Genital Tumours. Edition 5. WHO Classification of Tumours. 2020.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Boruban MC, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev. 2008;17(2):133-8. DOI:10.1097/CEJ.0b013e32811080ce</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Красильникова А.К., Малышкина Д.А., Гасанова С.М., и др. Факторы риска развития гиперплазии эндометрия с аномальными маточными кровотечениями у женщин репродуктивного возраста. Российский вестник акушера-гинеколога. 2023;23(6):48-54 [Krasil’nikova AK, Malyshkina DA, Hasanova SM, et al. Risk factors for the development of endometrial hyperplasia with abnormal uterine bleeding in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2023;23(6):48-54 (in Russian)]. DOI:10.17116/rosakush20232306148</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sanderson PA, Critchley HO, Williams AR, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232-54. DOI:10.1093/humupd/dmw042</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nees LK, Heublein S, Steinmacher S, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022;306(2):407-21. DOI:10.1007/s00404-021-06380-5</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ерофеева Л.Г., Сидоркина А.Г., Новопашина Г.Н., и др. Современное представление о проблеме гиперплазии эндометрия. Научное обозрение. Медицинские науки. 2022;6:82-8 [Erofeeva LG, Sidorkina AG, Novopashina GN, et al. Sovremennoe predstavlenie o probleme giperplazii endometriia. Nauchnoe obozrenie. Meditsinskie nauki. 2022;6:82-8 (in Russian)]. DOI:10.17513/srms.1308</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Собивчак М.С., Протасова А.Э., Раскин Г.А., и др. Злокачественная трансформация гиперпластических процессов эндометрия: иммуногистохимические особенности. Опухоли женской репродуктивной системы. 2022;18(3):89-99 [Sobivchak MS, Protasova AE, Raskin GA, et al. Malignant transformation of endometrial hyperplastic processes: immunohistochemical features. Tumors of female reproductive system. 2022;18(3):89-99 (in Russian)]. DOI:10.17650/1994-4098-2022-18-3-89-99</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Кулавский В.А., Пушкарев В.А., Кулавский Е.В., Пушкарев А.В. этиопатогенез гиперпластических процессов эндометрия у женщин репродуктивного возраста. Медицинский вестник Башкортостана. 2019;14(2):71-80 [Kulavsky VA, Pushkarev VA, Kulavsky EV, Pushkarev AV. Etiopathogenesis of endometrial hyperplastic processes in women of reproductive age. Bashkortostan Medical Journal. 2019;14(2):71-80 (in Russian)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Гиперплазия эндометрия. Клинические рекомендации Минздрава России. 2021. Режим доступа: https://www.diseases.medelement.com/disease/гиперплазия-эндометрия-кп-рф-2021/16965. Ссылка активна на 15.05.2025 [Giperplaziia endometriia. Klinicheskie rekomendatsii Minzdrava Rossii. 2021. Available at: https://www.diseases.medelement.com/disease/giperplaziia-endometriia-kp-rf-2021/16965. Accessed: 15.05.2025 (in Russian)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Сабанцев М.А., Шрамко С.В., Левченко В.Г., и др. Гиперплазии эндометрия: без атипии и с атипией. Гинекология. 2021;23(1):18-24 [Sabantsev MA, Shramko SV, Levchenko VG, et al. Endometrial hyperplasia: without atypia and with atypia. Gynecology. 2021;23(1):18-24 (in Russian)]. DOI:10.26442/20795696.2021.1.200666</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hui LS, Chin SHM, Goh C, et al. Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy. Obstet Gynecol Sci. 2021;64(3):300-8. DOI:10.5468/ogs.20294</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Протасова А.Э., Адамян Л.В., Собивчак М.С., Цыпурдеева А.А. Эндометриальная гиперплазия: современные концепции этиопатогенеза. Проблемы репродукции. 2023;29(4):75-80 [Protasova AE, Adamyan LV, Sobivchak MS, Tsypurdeeva AA. Endometrial hyperplasia: modern concepts of etiopathogenesis. Russian Journal of Human Reproduction. 2023;29(4):75-80 (in Russian)]. DOI:10.17116/repro20232904175</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Rosen MW, Tasset J, Kobernik EK, et al. Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger. J Pediatr Adolesc Gynecol. 2019;32(5):546-9. DOI:10.1016/j.jpag.2019.06.004</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Choi S, Lee YJ, Jeong JH, et al. Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. Front Oncol. 2021;11:636378. DOI:10.3389/fonc.2021.636378</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ring KL, Mills AM, Modesitt SC. Endometrial Hyperplasia. Obstet Gynecol. 2022;140(6):1061-75. DOI:10.1097/AOG.0000000000004989</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Каппушева Л.М., Михалева Л.М., Бреусенко В.Г., и др. Гормональная терапия у пациенток репродуктивного возраста с гиперплазией эндометрия без атипии. Иммуногистохимические предикторы эффективности. Российский вестник акушера-гинеколога. 2022;22(5):22-9 [Kappusheva LM, Mikhaleva LM, Breusenko VG, et al. Hormonal therapy in patients of reproductive age with endometrial hyperplasia without atypia. Immunohistochemical predictors of efficacy. Russian Bulletin of Obstetrician-Gynecologist. 2022;22(5):22-9 (in Russian)]. DOI:10.17116/rosakush20222205122</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Chandra V, Kim JJ, Benbrook DM, et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2015;27(1):e8. DOI:10.3802/jgo.2016.27.e8</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Оразов М.Р. Дискуссионные вопросы ведения пациенток с гиперплазией эндометрия. Акушерство и гинекология: Новости. Мнения. Обучения. 2016;3(13):46-58 [Orazov MR. Debating points of endometrium hyperplasia case management. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2016;3(13):46-58 (in Russian)].</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Nooh AM, Abdeldayem HM, Girbash EF, et al. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia. Reprod Sci. 2016;23(4):448-54. DOI:10.1177/1933719115623643</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Girbash EF, Sherif HE, Radwan AM, Abdeldayem HM. Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia. Arch Gynecol Obstet. 2023;308(3):947-52. DOI:10.1007/s00404-023-07015-7</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Uzelli SH, Simsek T, Duruksu G, et al. Different Effect of Dienogest on Endometrium Mesenchymal Stem Cells Derived from Healthy and Endometriosis Tissues. Balkan Med J. 2024;41(6):484-90. DOI:10.4274/balkanmedj.galenos.2024.2024-6-95</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Yao Y, Xu S, Wang T, Jiang R. Efficacy of drugs treatment in patients with endometrial hyperplasia with or without atypia: A systematic review and network meta-analysis. Medicine (Baltimore). 2024;103(38):e39619. DOI:10.1097/MD.0000000000039619</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477-82. DOI:10.1016/j.ygyno.2012.01.003</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Liegl S. Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia. Am Fam Physician. 2016;93(11):948-9.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>An H, Li T, Huang K, et al. Pregnancy outcomes in infertile patients with endometrial hyperplasia with or without atypia undergoing in vitro fertilization: the early-follicular long protocol is superior to midluteal long protocol. Front Endocrinol (Lausanne). 2024;15:1314432. DOI:10.3389/fendo.2024.1314432</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Sivalingarajah R, Kopalasundaram M. A Successful Fertility Outcome after Assisted Reproduction in a Woman with Endometrial Hyperplasia without Atypia Following Progesterone Therapy. Journal of South Asian Federation of Obstetrics and Gynaecology. 2023;15(3):349-51. DOI:10.5005/jp-journals-10006-2242</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Оразов М.Р., Михалева Л.М., Орехов Р.Е., Муллина И.А. Профилактика гиперплазии эндометрия без атипии у женщин репродуктивного возраста. Гинекология. 2021;23(5):454-8 [Orazov MR, Mihaleva LM, Orekhov RE, Mullina IA. Prevention of endometrial hyperplasia without atypia in women of reproductive age. Gynecology. 2021;23(5):454-8 (in Russian)]. DOI:10.26442/20795696.2021.5.201217</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Петровская С.А., Хамошина М.Б., Хасан А.Ш., и др. Современная парадигма риска атипической гиперплазии эндометрия: возможности прогнозирования. Акушерство и гинекология: новости, мнения, обучение. 2024;12:134-40 [Petrovskaya SA, Khamoshina MB, Hasan ASh. Modern risk paradigm for atypical endometrial hyperplasia: predictive capabilities. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2024;12:134-40 (in Russian)]. DOI:10.33029/2303-9698-2024-12-suppl-134-140</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Ордиянц И.М., Куулар А.А., Ямурзина А.А., Новгинов Д.С. Прогнозирование риска озлокачествления гиперплазии эндометрия в репродуктивном возрасте. Фундаментальная и клиническая медицина. 2020;5(1):57-63 [Ordiyants IM, Kuular AA, Yamurzina AA, Novginov DS. Predicting the risk of malignisation of endometrial hyperplasia in reproductive age. Fundamental and Clinical Medicine. 2020;5(1):57-63 (in Russian)]. DOI:10.23946/2500-0764-2020-5-1-57-63</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Петрожицкая А.А., Танделов Р.К., Зайцев Н.А., Морхов К.Ю. Органосохраняющее лечение атипической гиперплазии и рака эндометрия: современные тенденции. Злокачественные опухоли. 2023;13(2):69-79 [Petrozhitskaya AA, Tandelov RK, Zaitcev NA, Morkhov KY. Organ preservation treatment of patients with atypical hyperplasia and endometrial cancer: current trends. Malignant tumours. 2023;13(2):69-79 (in Russian)]. DOI:10.18027/2224-5057-2023-13-2-5</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Kamii M, Nagayoshi Y, Ueda K, et al. Laparoscopic Surgery for Atypical Endometrial Hyperplasia with Awareness Regarding the Possibility of Endometrial Cancer. Gynecol Minim Invasive Ther. 2023;12(1):32-7. DOI:10.4103/gmit.gmit_44_22</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Garzon S, Uccella S, Zorzato PC, et al. Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021;112(1):55-69. DOI:10.23736/S0026-4806.20.07072-X</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Annan HG, Guleria J. Beware: pregnancy and second-generation endometrial ablation. Gynecol Surg. 2005;2(3):209-10. DOI:10.1007/s10397-005-0120-x</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Kohn JR, Shamshirsaz AA, Popek E, et al. Pregnancy after endometrial ablation: a systematic review. BJOG. 2018;125(1):43-53. DOI:10.1111/1471-0528.14854</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Alabi C, Pickersgill A. Successful pregnancy after microwave endometrial ablation: case report. Gynecol Surg. 2007;5(2):155-6. DOI:10.1007/s10397-007-0343-0</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Hsieh K, Bloom JR, Dickstein DR, et al. Risk-Tailoring Radiotherapy for Endometrial Cancer: A Narrative Review. Cancers (Basel). 2024;16(7):1346. DOI:10.3390/cancers16071346</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Fan Y, Li X, Wang J, et al. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2021;19(1):118. DOI:10.1186/s12958-021-00808-y</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Chae SH, Shim SH, Lee SJ, et al. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2019;29(1):77-85. DOI:10.1136/ijgc-2018-000036</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Di Nisio V, Daponte N, Messini C, et al. Oncofertility and Fertility Preservation for Women with Gynecological Malignancies: Where Do We Stand Today? Biomolecules. 2024;14(8):943. DOI:10.3390/biom14080943</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Gonthier C, Walker F, Luton D, et al. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol. 2014;133(1):33-7. DOI:10.1016/j.ygyno.2013.11.007</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Contreras NA, Sabadell J, Verdaguer P, et al. Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions. Int J Mol Sci. 2022;23(5):2531. DOI:10.3390/ijms23052531</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016;3:8. DOI:10.1186/s40661-016-0029-2</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>European Society for Medical Oncology (ESMO) Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results from the RUBY Trial [ESMO Press Release]. Available at: https://www.esmo.org/newsroom/press-releases/latest-data-indicate-new-care-standard-in-advanced-recurrent-endometrial-cancer-results-from-the-ruby-tria. Accessed: 15.05.2025.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Chen J, Cao D. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases. World J Surg Oncol. 2024;22(1):169. DOI:10.1186/s12957-024-03439-w</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Chen J, Cao D, Yang J, et al. Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy. Front Oncol. 2021;11:738370. DOI:10.3389/fonc.2021.738370</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2020;31(1):12-39. DOI:10.1136/ijgc-2020-002230</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Piatek S, Michalski W, Sobiczewski P, et al. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review. Eur J Obstet Gynecol Reprod Biol. 2021;263:139-47. DOI:10.1016/j.ejogrb.2021.06.007</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Пронин С.М., Мацнева И.А., Новикова Е.Г. Возможности репродукции после лечения начального рака эндометрия. Акушерство и гинекология. 2018;10:100-4 [Pronin SM, Matsneva IA, Novikova EG. Possibilities of reproduction after treatment for early endometrial cancer. Obstetrics and Gynecology. 2018;10:100-4 (in Russian)]. DOI:10.18565/aig.2018.10.100-104</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Петрожицкая А.А., Танделов Р.К., Зайцев Н.А., и др. Органосохраняющее лечение атипической гиперплазии и рака эндометрия: современные тенденции. Злокачественные опухоли. 2023;2:69-79 [Petrozhitskaya AA, Tandelov RK, Zaitsev NA, et al. Organ-Preserving Treatment of Atypical Hyperplasia and Endometrial Cancer: Current Trends. Malignant Tumors. 2023;2:69-79 (in Russian)].</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Han Y, Liu C, Liu D, et al. Pregnancy outcomes in freeze-all versus fresh embryo transfer cycles of women with adenomyosis and endometriosis: a systemic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1507252. DOI:10.3389/fendo.2025.1507252</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Gullo G, Etrusco A, Cucinella G, et al. Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview. Int J Mol Sci. 2021;22(21):11825. DOI:10.3390/ijms222111825</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Lee JH, Choi YS. Cryopreservation of oocytes and embryos for fertility preservation. J Korean Med Assoc. 2022;65(6):338-44. DOI:10.5124/jkma.2022.65.6.338</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Sciorio R. Cryopreservation of human embryos and oocytes for fertility preservation in cancer and non cancer patients: a mini review. Gynecol Endocrinol. 2020;36(5):381-8. DOI:10.1080/09513590.2020.1719402</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Новикова Е.Г., Чулкова О.В., Филатова Ю.В. Функционально-щадящее лечение начального рака эндометрия у пациенток репродуктивного возраста. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009;4:80-3 [Novikova EG, Chulkova OV, Filatova IuV. Funktsional'no-shchadiashchee lechenie nachal'nogo raka endometriia u patsientok reproduktivnogo vozrasta. Vestnik RONTs im. N.N. Blokhina RAMN. 2009;4:80-3 (in Russian)].</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Shin W, Park S, Kang S, et al. The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis. J Ovarian Res. 2020;13(1). DOI:10.1186/s13048-020-00698-5</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Румянцев А.А. Рациональная последовательность терапии распространенного и метастатического рака эндометрия. Опухоли женской репродуктивной системы. 2022;18(2):119-26 [Rumyantsev AA. Efficient sequence of therapy for advanced and metastatic endometrial cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system. 2022;18(2):119-26 (in Russian)]. DOI:10.17650/1994-4098-2022-18-2-119-126</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Джанашвили Л.Г., Хачатрян Н.А., Назаренко Т.А., и др. Репродуктивная функция больных с атипической гиперплазией и раком эндометрия IA-стадии в анамнезе: когортное исследование. Гинекология. 2022;24(4):277-82 [Dzhanashvili LG, Khachatryan NA, Nazarenko TA, et al. The reproductive function of patients with prior atypical endometrial hyperplasia and endometrial cancer treatment: cohort study. Gynecology. 2022;24(4):277-82 (in Russian)]. DOI:10.26442/20795696.2022.4.201670</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Нечушкина В.М., Коломиец Л.А., Кравец О.А., и соавт. Рак тела матки и саркомы матки. Клинические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли. 2025;15(3s2):170-94 [Nechushkina VM, Kolomiets LA, Kravets OA, et al. Rak tela matki i sarkomy matki. Klinicheskie rekomendatsii RUSSCO, chast' 1.2. Zlokachestvennye opukholi. 2025;15(3s2):170-94 (in Russian)]. DOI:10.18027/2224-5057-2025-15-3s2-1.2-06</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Новикова О.В., Новикова Е.Г., Волченко Н.Н., и соавт. Лечение рецидивов атипической гиперплазии и начального рака эндометрия после самостоятельной гормонотерапии. Акушерство и гинекология: новости, мнения, обучение. 2018;1:68-76 [Novikova OV, Novikova EG, Volchenko NN, et al. Treatment of recurrences of atypical hyperplasia and early endometrial cancer after prior conservative treatment. Obstetrics and Gynecology: News, Opinions, Training. 2018;1:68-76 (in Russian)].</mixed-citation></ref></ref-list></back></article>
